Interim Report, January – September 2007

Key events in the third quarter
• ONCOlog Medical out-licenses clinical cobalt technology based radiotherapy solution
• Biovator and AstraZeneca enter into an agreement for allergen test development
• Anders Karlsson takes up the position of COO for AbSorber
• Okee Williams from Elekta joins LinkMed as new Portfolio Manager


Key events after the period end
• LinkMed invests SEK 4 million in new portfolio company
• Ortoviva to start clinical trial phase in early 2008


Financial information for the first nine months 2007
• Earnings from investment activities totaled SEK 0.0 million (0.0)
• Other revenues increased to SEK 3.7 million (2.8), of which SEK 1.2 million (1.0) in the third quarter
• Earnings after tax were SEK -5.9 (-10.4) million, of which SEK -1.7 million (-4.3) in the third quarter
• Earnings per share were SEK -0.68 (-2.00)
• Shareholders’ equity was SEK 290.3 million, compared to SEK 296.2 million at December 31, 2006. Shareholders’ equity per share was SEK 33.28 (33.96)
• Equity/assets ratio was 98 percent (97 percent at December 31, 2006)
• Liquid funds amounted to SEK 146.5 million (SEK 202.7 million at December 31, 2006)


Comments from LinkMed CEO, Ingemar Lagerlöf:
“To our great satisfaction we see that ONCOlog Medical reported a profit during the third quarter. The company is in talks with key players and great interest is being shown in ONCOlog Medical’s know-how and technology. Going forward, the company’s development will be very interesting.”
It is also a pleasure to report that clinical evaluation of Ortoviva’s development project will start earlier than expected. Distractor will solve major problems within the area of spinal surgery.”



For additional information, please contact:
Ingemar Lagerlöf, CEO, cell: +46 70-873 2733, ingemar.lagerlof@linkmed.se
Jan Mattsson, CFO, cell: 070-833 8999, jan.mattsson@linkmed.se